AC Immune, Genentech in second antibody deal for AD

AC Immune S.A. (Lausanne, Switzerland) partnered with Genentech Inc. to develop and commercialize antibodies against microtubule-associated protein tau (MAPT; tau; FTDP-17) for Alzheimer's disease and other neurodegenerative indications. The partners will identify preclinical candidates from a collection of antibodies discovered using AC Immune's SupraAntigen technology, and will use their respective technologies to discover additional antibodies. Genentech has exclusive, worldwide rights to develop and commercialize antibodies resulting from the multi-year deal. AC Immune will receive an undisclosed upfront payment and is eligible for more than $418 million in milestones, plus royalties. Details were not disclosed. ...